目前用于预防带状疱疹的疫苗。
Current vaccines for the prevention of herpes zoster.
机构信息
University of Miami Miller School of Medicine/ Bascom Palmer Eye Institute.
Miami Veterans Affairs Medical Center, Miami, Florida, USA.
出版信息
Curr Opin Ophthalmol. 2018 Jul;29(4):355-359. doi: 10.1097/ICU.0000000000000480.
PURPOSE OF REVIEW
To summarize the recent advances in the prevention of herpes zoster. The recent Food and Drug Administration (FDA) approval of an adjuvanted subunit vaccine may have a significant impact on the prevention of herpes zoster ophthalmicus.
RECENT FINDINGS
There are currently two commercially available vaccines for the prevention of herpes zoster: a live-attenuated vaccine and a new recombinant subunit vaccine. The latter has been shown to be more effective, have fewer contraindications, but requires two separate inoculations, has higher reactogenicity, and has only short-term postmarketing surveillance.
SUMMARY
The adjuvanted zoster subunit vaccine offers several advantages over the previously available vaccine. Following the current treatment recommendations, physicians should recommend vaccination to all patients older than 50 years of age with no contraindications, this should also prevent ophthalmic complications of the disease.
目的综述
总结带状疱疹预防的最新进展。最近食品和药物管理局（FDA）批准的一种佐剂亚单位疫苗可能对预防眼带状疱疹有重大影响。
最近的发现
目前有两种可用于预防带状疱疹的商业疫苗：减毒活疫苗和新型重组亚单位疫苗。后者已被证明更有效，禁忌症更少，但需要两次单独接种，反应原性更高，且仅进行短期上市后监测。
总结
佐剂带状疱疹亚单位疫苗相对于以前的可用疫苗具有几个优势。根据目前的治疗建议，对于没有禁忌症的所有 50 岁以上的患者，医生应推荐接种疫苗，这也应该预防疾病的眼部并发症。
Zotero 插件